drugset
Drugs / BMS-986368
last change 5 days ago re-read 9 days ago

BMS-986368

also known as CC-97489 · Irafamdastat

targets FAAH via inhibition

Developed for
multiple sclerosis
Investigated by
Celgene Corporation · Alberto Esquenazi · Bristol-Myers Squibb

Trials 10

today NCT07700329 · Ph 1 NCT07837115 · Ph 1 NCT07704840 · Ph 2 NCT06808984 · Ph 2 NCT06782490 · Ph 2 NCT06411730 · Ph 1 NCT06170723 · Ph 1 NCT06227975 · Ph 1 NCT05065541 · Ph 1 NCT05099822 · Ph 1
202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT07700329 Jan → Feb 2027 expected — Celgene Corporation Not yet recruiting No outcome recorded
Phase 1 NCT07837115 Oct → Dec 2026 expected — Celgene Corporation Not yet recruiting No outcome recorded
Phase 1 NCT06411730 May → Oct 2024 — Celgene Corporation Completed No outcome recorded
Phase 1 NCT06170723 Mar → May 2024 — Celgene Corporation Completed No outcome recorded
Phase 1 NCT06227975 Feb → Apr 2024 — Celgene Corporation Completed No outcome recorded
Phase 1 NCT05065541 Sep 2021 → Jan 2024 — Celgene Corporation Completed No outcome recorded
Phase 1 NCT05099822 Mar 2020 → Jul 2022 — Celgene Corporation Terminated No outcome recorded Stop: Business
Phase 23 trials
Phase 2 NCT07704840 Sep 2026 → Jun 2027 expected — Alberto Esquenazi Recruiting No outcome recorded
Phase 2 NCT06808984 Jun 2025 → Nov 2027 expected Alzheimer disease Celgene Corporation Recruiting No outcome recorded
Phase 2 NCT06782490 Jun 2025 → May 2027 expected multiple sclerosis Celgene Corporation Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as BMS-986368 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06782490 ↗
6

NCT06170723 ↗

NCT06227975 ↗

NCT06411730 ↗

NCT06808984 ↗

NCT07700329 ↗

NCT07704840 ↗
Known as CC-97489 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065541 ↗
1

NCT05099822 ↗
Known as Irafamdastat ClinicalTrials.gov intervention name — accepted as the source's own label NCT07837115 ↗
Action Inhibit “BMS-986368, a FAAH/MAGL Inhibitor” NCT06782490 ↗
Route Oral “oral administration of single and multiple doses of CC-97489” NCT05065541 ↗
Target FAAH “BMS-986368, a FAAH/MAGL Inhibitor” NCT06782490 ↗